Michael Schlosser, Ph.D., DABT
Michael Schlosser, Ph.D., DABTChief Executive Office
Prior to joining Hera, Mike Schlosser worked at companies such as Pfizer and Astra Pharmaceuticals and brings a strong track record in drug discovery and development, in-licensing due diligence, acquisitions, integrations and startup companies. Mike founded and served as President of Midwest BioResearch, and then as Vice President at WIL Research and as a research consultant focused on translational drug discovery and development for pharmaceutical, biotechnology, venture capital and academic partners.
Jack Crawford, M.S.
Jack Crawford, M.S.Vice President, Business Development
Mr. Crawford formerly directed the Sales, Marketing, and Business Development Divisions at Transposagen Biopharmaceuticals, Inc. He has experience private equity financing, product development, licensing, technology and patent evaluation. He contributed to nearly all aspects of Transposagen’s rise from pre-revenue start-up to $100M+ valuation (including spin-outs). At Hera, Mr. Crawford is responsible for fundraising, revenue generation, intellectual property development, licensing and corporate governance. Mr. Crawford holds a BS in Biochemistry from Virginia Tech and a Masters in Biotechnology from University of Pennsylvania.
Tseten Yeshi, Ph.D.
Tseten Yeshi, Ph.D.Vice President, Research & Development
Former Director of R&D at Transposagen. Dr. Yeshi is a molecular biologist and expert in genome editing and with full range experience in performing complex gene editing in a broad array of cell types including rodent embryonic stem cells and spermatogonial stem cells. He has hands on start to finish experience in targeted nuclease design, their on-target and off-target cutting analysis, creation of custom cell lines and rodent models, performing wide-range of molecular and cellular assays for their characterization. Dr. Yeshi has worked extensively with CRISPR/Cas9, TALEN and piggyBac technologies. Particularly combining these technologies for efficient Footprint Free Gene editing: making precise mutations without leaving any undesired changes or “footprint” behind in the genome. Dr. Yeshi has well-developed scientific program management skills and experience, has been a Principle Investigator on multiple NIH SBIR grants and a co-inventor of several patents.
Fallon Noto, Ph.D.
Fallon Noto, Ph.D. Executive Director, R&D/In Vivo Services
Dr. Noto has 10+ years working with mice and rats, expertise in rodent humanization, cell and tissue transplantation, microsurgery, and ethical animal care with 10+ publications in the field. She is proficient in cell culture techniques of mammalian cells, primary cells, and pluripotent stem cells, including differentiation assays and viral transduction. Dr. Noto is skilled in molecular techniques, including tissue histology, PCR, and protein expression analysis.
Valeriya Steffey, M.D.
Valeriya Steffey, M.D.Director, In Vitro Services
Dr. Valeriya Steffey worked for Transposagen Biopharmaceuticals Inc. for over ten years, prior to joining Hera, where she distinguished herself as an innovative leader in both technology and business development. Dr. Steffey was the Director of Cell Line Engineering at Transposagen. Under her management, her team had a proven track record of successful completion of cell line engineering, engineered animal models and R&D projects. In addition to her experience in the biotechnology industry, Dr. Steffey practiced medicine for over ten years and performed academic research, with an emphasis in anatomy and neurobiology, providing her with a broad and varied background. She is a published author and co-author of many scientific articles.
Goutham Narla, M.D., Ph.D.
Goutham Narla, M.D., Ph.D.SAB Member & Consultant
The Pardee Gerstacker Professor of Cancer Research and a Medical geneticist at Case Western Reserve University. Dr. Narla is the CSO and Scientific Founder of Dual Therapeutics, Inc. He has expertise in cancer genetics and xenograft and transgenic models of cancer with over 58 publications in the field.
Chris Brenzel
Chris BrenzelSr. Director, Business Development/Gene Editing Solutions
Chris has been with Hera BioLabs since its inception in 2015. He has extensive experience in scientific business development, market research, and licensing for startups and fast-growing technology-based contract research organizations. He grew the gene-editing and animal models development businesses at Transposagen Biopharmaceuticals, a company acquired by Hera BioLabs in 2018. Chris has a BS in Biological Sciences from Notre Dame with focus on Business Technology and Entrepreneurship. Contact Chris at cbrenzel @ herabiolabs.com or 859-414-0648.